4//SEC Filing
ARIAD PHARMACEUTICALS INC 4
Accession 0001127602-15-027731
CIK 0000884731operating
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 5:40 PM ET
Size
10.9 KB
Accession
0001127602-15-027731
Insider Transaction Report
Form 4
Haluska Frank
VP, Clinical R&D, CMO
Transactions
- Award
Performance stock unit
2015-09-24+20,000→ 20,000 total→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2015-09-24+10,000→ 127,724 total - Sale
Common Stock
2015-09-28$6.46/sh−5,500$35,503→ 122,224 total - Exercise/Conversion
Performance stock unit
2015-09-24−10,000→ 10,000 total→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]Shares were acquired upon vesting of performance stock units awarded on March 19, 2013.
- [F2]Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.22 to $6.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- [F4]Each performance stock unit represents a right to receive one share of ARIAD common stock.
- [F5]The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/24/2016.
Documents
Issuer
ARIAD PHARMACEUTICALS INC
CIK 0000884731
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000884731
Filing Metadata
- Form type
- 4
- Filed
- Sep 27, 8:00 PM ET
- Accepted
- Sep 28, 5:40 PM ET
- Size
- 10.9 KB